Company: BNBX
Filing Date: 2025-01-17
Form Type: 424B3
Source: 0001104659-25-004510
Chunk: 20

Company: BNB PLUS CORP.
Filing Date: 2025-01-17
Form: 424B3
Chunk 20
---
We may not be able to fully implement our business
strategies or realize, in whole or in part within the expected time frames, the anticipated benefits of our various growth or other initiatives.
Our various business strategies and initiatives, including our growth, operational and management initiatives and the development in
particular of our Therapeutic DNA Production Services, are subject to business, economic and competitive uncertainties and contingencies,
many of which are beyond our control. The execution of our business strategy and our financial performance will continue to depend in
significant part our ability to obtain sufficient financing and on our executive management team and other key management personnel,
our ability to identify and complete suitable acquisitions, our executive management team’s ability to execute new operational
initiatives, and certain matters outside of our control. In addition, we may incur certain costs as we pursue our growth, operational
and management initiatives, and we may not meet anticipated implementation timetables or stay within budgeted costs. As these initiatives
are undertaken, we may not fully achieve our expected efficiency improvements or growth rates, or these initiatives could adversely impact
our customer retention, supplier relationships or operations. Also, our business strategies may change from time to time in light of
our ability to implement our business initiatives, competitive pressures, economic uncertainties or developments, or other factors.

We may modify and refine our business strategy, includinga possible closure or divesture of our DNA Tagging and Security Products and Services and/or MDx Testing Services segments.

Our management is currently engaged in a strategic
review of the Company’s business segments that may result in the closure or divestiture of the Company’s DNA Tagging and
Security Products and Services segment and/or MDx Testing Services, as well as workforce reductions and potential management changes.
To this end, on December 17, 2024, the Company announced it is exploring the potential closure or divestiture of its DNA Tagging and
Security Products and Services business segment. No assurance can be given that a closure or divestiture will be completed. Further,
the definitive terms and structure of any possible closure or divestiture have not been determined or approved by the Company’s
Board of Directors. Although the purpose of any closure or divestiture would be to reduce the Company’s expenses and effectuate
cost savings, it is possible that there may be related restructuring costs. We expect that based on available opportunities and our beliefs
regarding future opportunities, we will continue to modify and refine our business strategy. The initial cash received from any closure